Article

A non-covalent peptide-based strategy for siRNA delivery: Figure 1

French National Centre for Scientific Research, Lutetia Parisorum, Île-de-France, France
Biochemical Society Transactions (Impact Factor: 3.19). 03/2007; 35(Pt 1):44-6. DOI: 10.1042/BST0350044
Source: PubMed

ABSTRACT

The major obstacle to clinical development of siRNAs (short interfering RNAs), like for most of the nucleic-acid-based strategies, is their poor cellular uptake and bioavailability. Although several viral and non-viral strategies have been proposed to improve siRNA delivery, their applications in vivo remain a major challenge. We have developed a new strategy, based on a short amphipathic peptide, MPG, that is able to form stable nanoparticles with siRNA. MPG-based particles enter the cell independently of the endosomal pathway and can efficiently deliver siRNA in a fully biologically active form into a variety of cell lines and in vivo. This short review will discuss the mechanism and the potency of the MPG strategy for siRNA delivery both in vitro and in vivo.

Download full-text

Full-text

Available from: Laurence Crombez (Campion)
  • Source
    • "Studies by Simeoni and colleagues suggest MPG exhibits high affinity in the nanomolar range for siRNA and that approximately 10 to 20 peptide molecules are required to form a highly stable nanoparticle (Simeoni et al., 2003). The presence of a peptide-based nanostructure associated to the siRNA dramatically improved its stability inside the cell and significantly protected it from degradation (Crombez et al., 2007). The internalization process of MPG according to Deshayes et al. (2004) is achieved through formation of a carrier/cargo complex and occurs through a nonendosomal pathway leading to a mainly nuclear final localization of the cargo. "

    Preview · Article · Sep 2015 · AFRICAN JOURNAL OF BIOTECHNOLOGY
  • Source
    • "Polyethyleneimines (PEI) are polycation-containing block copolymers (Muratovska & Eccles 2004), which have also been used for delivery of siRNA molecules in vivo, although PEI use in vivo has some toxicity issues (Crombez et al. 2009). Chitosan is a biodegradable, biocompatible and non-toxic cationic polymer obtained from deacetylation of chitin, which has been proposed as biocompatible alternative to cationic polymers, suitable for non-viral nucleic acid delivery (Crombez et al. 2007). Chitosans have been used for siRNA delivery in vitro as well as in vivo (Kumar et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Soon after discovery of RNA interference (RNAi), its potential as eff ective antiviral therapy was recognized. Since then RNAi has been variously exploited for antiviral purposes which could eff ectively block viral replication in vitro. For in vivo use, however, delivery issue, toxicity, RNAi suppression and viral escape are still major hurdles. Here, we provide an overview of the RNAi strategy and review the approaches that have been developed to surpass the obstacles and to achieve targeted gene silencing for antiviral and other therapies.
    Full-text · Article · Jan 2013
  • Source
    • "The covalent linkage of CPPs to siRNAs results in the formation of small, monomeric CPP/siRNA conjugates of known stoichiometry with high reproducibility [26]. CPPs could therefore be used for delivery of siRNAs either by covalent or non-covalent approaches [27]. However non-covalent strategies are more efficient for siRNA delivery, for example MPG peptide has been extensively reported to improve siRNA delivery into a large panel of cell lines including adherent cell lines, cells in suspension, cancer and challenging primary cell lines biological response [28,29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The cell membrane is a highly selective barrier. This limits the cellular uptake of molecules including DNA, oligonucleotides, peptides and proteins used as therapeutic agents. Different approaches have been employed to increase the membrane permeability and intracellular delivery of these therapeutic molecules. One such approach is the use of Cell Penetrating Peptides (CPPs). CPPs represent a new and innovative concept, which bypasses the problem of bioavailability of drugs. The success of CPPs lies in their ability to unlock intracellular and even intranuclear targets for the delivery of agents ranging from peptides to antibodies and drug-loaded nanoparticles. This review highlights the development of cell penetrating peptides for cell-specific delivery strategies involving biomolecules that can be triggered spatially and temporally within a cell transport pathway by change in physiological conditions. The review also discusses conjugations of therapeutic agents to CPPs for enhanced intracellular delivery and bioavailability that are at the clinical stage of development.
    Full-text · Article · Dec 2012
Show more